Market Place
Sourcing Support
CytRx guns for a reset, rebranding as LadRx
26 Sep 2022 //
FIERCEPHARMA
CytRx Corporation Relaunches as LadRx Corporation
23 Sep 2022 //
BUSINESSWIRE
CytRx Announces Distribution of Series D Preferred Stock to Holders
19 May 2022 //
BUSINESSWIRE
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
17 May 2022 //
BUSINESSWIRE
CytRx Partners with Oncology Development Expert to Advance LADR Platform
20 Apr 2022 //
BUSINESSWIRE
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
21 Mar 2022 //
BUSINESSWIRE
CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma
09 Mar 2022 //
BUSINESSWIRE
Orphazyme to assess strategic options after EU advisers nix drug
25 Feb 2022 //
BIOSPACE
CytRx Highlights Orphazyme`s Update on Planned NDA Resubmission for Arimoclomol
14 Feb 2022 //
BUSINESSWIRE
CytRx Highlights ImmunityBio`s Use of Aldoxorubicin in Various Forms of Cancer
21 Dec 2021 //
BUSINESSWIRE
CytRx Highlights ImmunityBio`s Completion of Enrollment in Phase 2 Study
14 Oct 2021 //
BUSINESSWIRE
CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep 2021 //
BUSINESSWIRE
CytRx Highlights Orphazyme’s Results From Its Phase 2/3 Trial of Arimoclomol
24 Aug 2021 //
BUSINESSWIRE
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
12 Aug 2021 //
BUSINESSWIRE
CytRx Highlights Preliminary Results of Cohort C of QUILT 88
29 Jul 2021 //
BUSINESSWIRE
CytRx Announces Director Election Results from 2021 Annual Meeting
29 Jul 2021 //
BUSINESSWIRE
CytRx Corporation Announces Closing of $10 Million Offering
16 Jul 2021 //
BUSINESS WIRE
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million
13 Jul 2021 //
BUSINESSWIRE
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results
30 Jun 2021 //
BUSINESSWIRE
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol
21 Jun 2021 //
BUSINESSWIRE
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol
18 Jun 2021 //
BUSINESSWIRE
Orphazyme and CytRx skyrocket ahead of FDA decision on Arimoclomol
10 Jun 2021 //
SEEKING ALPHA
CytRx Comments on Quarterly Results and Year-to-Date Progress
13 May 2021 //
BUSINESSWIRE
CytRx Notes Orphazyme’s Announcement of Topline Results from Trial Arimoclomo
01 Apr 2021 //
BUSINESSWIRE
Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol
08 Mar 2021 //
BUSINESSWIRE
CytRx Highlights Use of Aldoxorubicin in Ph 2 Clinical Trials Yielding Positive
15 Jan 2021 //
BUSINESSWIRE
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding
15 Jan 2021 //
NEWS
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol
01 Jan 2021 //
BUSINESSWIRE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
22 Dec 2020 //
BUSINESSWIRE
CytRx Highlights Orphazyme’s Acceleration of Pre-Launch for Arimoclomol
27 Oct 2020 //
BUSINESSWIRE
CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Ph 2 Study
13 Oct 2020 //
PRESS RELEASE
CytRx Highlights Use of Licensed Drug Aldoxorubicin
07 Oct 2020 //
BUSINESSWIRE
CytRx Issues Statement Regarding Orphazyme’s Global Offering
30 Sep 2020 //
BUSINESSWIRE
CytRx Issues Statement Regarding Orphazyme’s Global Offering
29 Sep 2020 //
BUSINESSWIRE
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance
17 Sep 2020 //
BIOSPACE
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review
16 Sep 2020 //
BUSINESSWIRE
CytRx Announces Voting Results from 2020 Annual Meeting
03 Sep 2020 //
BUSINESSWIRE
CytRx Announces Initiatives to Strengthen Corporate Governance
24 Aug 2020 //
BUSINESSWIRE
CytRx Corporation Highlights Orphazyme`s Completion of Rolling sNDA
21 Jul 2020 //
PRNEWSWIRE
CytRx Corporation Highlights Orphazyme`s Announcement of its Phase 2 Study
29 Jun 2020 //
PRNEWSWIRE
CytRx Corporation Highlights Orphazyme`s Rolling Submission of its NDA
01 Jun 2020 //
PRNEWSWIRE
CytRx Corporation Highlights Orphazyme`s Receipt of FDA Fast Track Designation
26 May 2020 //
PR NEWSWIRE
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance
29 Apr 2020 //
PR NEWSWIRE
CytRx Corporation Clarifies Prior Disclosures its Relationship with Orphazyme
28 Feb 2020 //
PR NEWSWIRE
CytRx Corporation Highlights Updated Arimoclomol Milestone Licensee Orphazyme
04 Feb 2020 //
PR NEWSWIRE
CytRx Corporation Highlights Significant +ve its Licensed Drug Aldoxorubicin
29 Jan 2020 //
PR NEWSWIRE
